Skip to main content

Advertisement

Table 2 Association of the four single-nucleotide polymorphisms with changes in Disease Activity Score in 28 joints at 6 and 12 months in Spanish rheumatoid arthritis patients a

From: Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis

    6 months 12 months
    Collection 1 (N= 419)   Collection 2 (N= 193)   Collection 1 (N= 314)   Collection 2 (N= 134)  
SNP Locus 1/2 MAF P-valueb βb MAF P-valueb βb MAF P-valueb βb MAF P-valueb βb
rs12081765 Intergenic A/G 0.415 0.570 0.055 0.458 0.995 0.001 0.411 0.716 0.043 0.408 0.677 0.062
rs1532269 PDZ2D C/G 0.375 0.831 0.020 0.418 0.830 0.022 0.400 0.647 0.051 0.420 0.022 0.335
rs17301249 EYA4 C/G 0.121 0.181 −0.190 0.132 0.458 0.120 0.131 0.416 −0.137 0.154 0.529 0.135
rs7305646 Intergenic T/C 0.474 0.244 −0.117 0.487 0.661 −0.049 0.486 0.182 −0.161 0.473 0.554 −0.093
  1. a1, Minor allele, 2, Major allele; MAF, Minor allele frequency; SNP, Single-nucleotide polymorphism. bAdjusted for gender, anti–tumor necrosis factor treatment and Disease Activity Score in 28 joints at baseline.